Evidence map›Paper›PMID 33166788›Full record

ArticleEBioMedicine2020

High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients.

Elena Yeregui, Consuelo Viladés, Pere Domingo, Andra Ceausu, Yolanda María Pacheco, Sergi Veloso, Alexy Inciarte, Judit Vidal-González, Maria Peraire, Carles Perpiñán and 10 more

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Persistent CD8Frontiers in immunology · 2026
    Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 1 country.

Elena YereguiUniversitat Rovira i Virgili, Tarragona, Spain; Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Consuelo ViladésUniversitat Rovira i Virgili, Tarragona, Spain; Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Pere DomingoInfectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Andra CeausuUniversitat Rovira i Virgili, Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Yolanda María PachecoLaboratory of Immunology, Institute of Biomedicine of Seville, IBiS, Seville, Spain; UGC Clinical Laboratories, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
Sergi VelosoUniversitat Rovira i Virgili, Tarragona, Spain; Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Alexy InciarteDepartment of Infectious Diseases, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.
Judit Vidal-GonzálezDepartment of Internal Medicine - Hepatology, Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain; Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Maria PeraireHospital Universitari Son Espases, Palma, Illes balears, Spain.
Carles PerpiñánCAP Sant Pere, Reus, Tarragona, Spain.
Vicenç FalcóVall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Jenifer MasipUniversitat Rovira i Virgili, Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Verónica AlbaUniversitat Rovira i Virgili, Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Montserrat VargasUniversitat Rovira i Virgili, Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Anna MartíUniversitat Rovira i Virgili, Tarragona, Spain; Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Laia RevertéUniversitat Rovira i Virgili, Tarragona, Spain; Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Josep MallolasDepartment of Infectious Diseases, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.
Francesc VidalUniversitat Rovira i Virgili, Tarragona, Spain; Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain. Electronic address: fvidalmarsal.hj23.ics@gencat.cat.
Joaquim PeraireUniversitat Rovira i Virgili, Tarragona, Spain; Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Anna RullUniversitat Rovira i Virgili, Tarragona, Spain; Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain; Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
Hospital Universitari Joan XXIII de Tarragona · ESUniversidad Rovira i Virgili · ESUniversitat de Barcelona · ESHospital de Sant Pau · ESHospital Universitario Son Espases · ESInstitut d'Investigació Sanitària Pere Virgili · ESInstituto de Biomedicina de Sevilla · ESVall d'Hebron Hospital Universitari · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe underlying mechanisms of incomplete immune reconstitution in treated HIV-positive patients are very complex and may be multifactorial, but perturbation of chemokine secretion could play a key role in CD4

methodsWe evaluated the circulating baseline and 48-week follow-up concentrations of SDF-1/CXCL12, fractalkine/CX3CL1, MCP-1/CCL2, MIP-α/CCL3, MIP-β/CCL4 and RANTES/CCL5, and we estimated their association with CXCL12, CX3CR1, CCR2, CCL5 and CCR5 single nucleotide polymorphisms (SNPs) to investigate multiple chemokine-chemokine receptor signatures associated with immune dysregulation preceding poor immune recovery.

findingsThe circulating concentrations and gene expression patterns of SDF-1/CXCL12 (CXCL12 rs1801157) and MCP-1/CCL2 (CCR2 rs1799864_814) were associated with immune recovery status. CCR2 rs1799864_814 and CCR5 rs333_814 (Δ32) determine the baseline plasma RANTES and MIP-α concentrations, respectively, in participants with poor immune response.

interpretationSDF-1/CXCL12 and MCP-1/CCL2 could be considered prognostic markers of immune failure despite suppressive antiretroviral therapy. The strong linkage disequilibrium (LD) between CCR2 rs1799864_814 and CCR5 rs1800024 indicated that the alleles of each gene are inherited together more often than would be expected by chance.

fundingThis work was supported by Fondo de Investigacion Sanitaria and SPANISH AIDS Research Network (ISCIII-FEDER); AGAUR and Gilead Fellowship. FV and YMP are supported by grants from the Programa de Intensificación (ISCIII) and Servicio Andaluz de Salud, respectively. JVG,EY and LR are supported by the Instituto de Salud Carlos III (ISCIII). AR is supported by Departament de Salut, Generalitat de Catalunya and by the Instituto de Salud Carlos III (ISCIII).

Indexed as

Genetic VariationAdultAllelesAntiretroviral Therapy, Highly ActiveCase-Control StudiesCD4 Lymphocyte CountChemokine CCL2Chemokine CXCL12FemaleGenetic Association StudiesGenotypeHIV InfectionsHumansImmunityImmunomodulationMaleCCL2 protein, humanCCR5 protein, humanChemokine CCL2Chemokine CXCL12CXCL12 protein, humanReceptors, CCR5Chemokine receptorsChemokinesHIVPolymorphisms variantsPoor immune recovery

Identifiers

PMID33166788
PMCPMC7653063
OpenAlexW3094864132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.